These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12123801)

  • 1. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.
    Karvonen U; Jänne OA; Palvimo JJ
    FEBS Lett; 2002 Jul; 523(1-3):43-7. PubMed ID: 12123801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
    Berrevoets CA; Veldscholte J; Mulder E
    J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor.
    Meyer R; Wolf SS; Obendorf M
    J Steroid Biochem Mol Biol; 2007 Oct; 107(1-2):1-14. PubMed ID: 17587566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-activator and co-repressor interplay on the human androgen receptor.
    Papaioannou M; Reeb C; Asim M; Dotzlaw H; Baniahmad A
    Andrologia; 2005 Dec; 37(6):211-2. PubMed ID: 16336251
    [No Abstract]   [Full Text] [Related]  

  • 7. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
    Miyamoto H; Yeh S; Wilding G; Chang C
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7379-84. PubMed ID: 9636157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
    Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
    Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P; Hersmus R; Trapman J; Houtsmuller AB
    J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
    Kang Z; Jänne OA; Palvimo JJ
    Mol Endocrinol; 2004 Nov; 18(11):2633-48. PubMed ID: 15308689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection.
    Nguyen TV; Yao M; Pike CJ
    Endocrinology; 2007 Jun; 148(6):2936-43. PubMed ID: 17347309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
    Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
    Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.
    Avancès C; Georget V; Térouanne B; Orio F; Cussenot O; Mottet N; Costa P; Sultan C
    Mol Cell Endocrinol; 2001 Nov; 184(1-2):13-24. PubMed ID: 11694337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
    Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S
    Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
    Steinsapir J; Mora G; Muldoon TG
    Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells.
    Tyagi RK; Lavrovsky Y; Ahn SC; Song CS; Chatterjee B; Roy AK
    Mol Endocrinol; 2000 Aug; 14(8):1162-74. PubMed ID: 10935541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
    Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
    J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC; Astapova I; Hollenberg AN; Balk SP
    Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.